home Startseite arrow_back zurück

  • Intranet für Studierende und Mitarbeitende

  • north_east Forschungsinformationssystem (FIS)

  • north_east Jobbörse

  • north_east Mensa

  • north_east mySpoho

  • Personenverzeichnis

  • north_east Spohoshop

  • Zentralbibliothek
home Startseite arrow_back zurück

  • Universität

    • Universität

    • Profil

      • Profil

      • Porträt

      • Unser Leitbild

      • Zahlen und Fakten

      • Auszeichnungen und Preise

      • Gleichstellung und Diversität

        • Gleichstellung und Diversität

        • Karriereförderung für Frauen

      • Nachhaltigkeit und Umweltschutz

      • International

        • International

        • Hochschulpartnerschaften

      • Partnerschaften und Kooperationen

        • Partnerschaften und Kooperationen

        • Kooperationsmöglichkeiten

    • Organisation

      • Organisation

      • Hochschulleitung

        • Hochschulleitung

        • Das Rektorat

          • Das Rektorat

          • Amtliche Mitteilungen

        • Der Senat

        • Der Hochschulrat

      • Verwaltung und Stabsstellen

      • Organe und Gremien

        • Organe und Gremien

        • Universitätskommissionen

        • Gleichstellungskommission

        • Nachhaltigkeitskommission

        • Ethikkommission

        • Prüfungsausschüsse

        • Promotionsausschuss

        • Habilitationsausschuss

      • Institute und wissenschaftliche Einrichtungen

      • Anlaufstellen und Services

        • Anlaufstellen und Services

        • Ambulanz

        • Career Service

        • Familienservice

        • Gästehaus

        • InfoPoint

        • International Office

        • Marketing

          • Marketing

          • Spohoshop

        • Presse und Kommunikation

        • Prüfungsamt

        • Studienberatung

        • Studierendensekretariat

        • Zentrale Betriebseinheit Informationstechnologie

      • Personenverzeichnis

    • Die Uni als Arbeitgeberin

      • Die Uni als Arbeitgeberin

      • Unsere Stellenangebote

      • Praktikum

        • Praktikum

        • Übersicht Praktikumsstellen

      • Personalentwicklung

      • Gesundheitsmanagement

    • Campusleben

      • Campusleben

      • Sport und Kultur

      • Wohnen und Übernachten

    • Newsroom

      • Newsroom

      • Podcast

        • Podcast

        • Wissenschaftspodcast Eine Runde mit

        • Studierendenpodcast Auszeit

      • Termine & Veranstaltungen

      • Meldungen

        • Meldungen

        • Pressemitteilungen

      • Publikationen

        • Publikationen

        • Campusmagazin ZeitLupe

          • Campusmagazin ZeitLupe

          • Sport und Ernährung

          • Olympische Spiele in Köln?

          • Gefahr im Gedränge

          • Darts - Ist das wirklich Sport?

        • Jahresbericht KOMPAKT

        • ZSLS

          • ZSLS

          • Hinweise für Autor*innen

          • Aktuelles

          • Impressum

      • Presseverteiler

      • Proband*innennewsletter

      • Pressespiegel

  • Studium

    • Studium

    • Vor dem Studium

      • Vor dem Studium

      • Veranstaltungen für Studieninteressierte

      • Bachelorstudium

        • Bachelorstudium

        • Sport- und Bewegungsvermittlung in Freizeit- und Breitensport

        • Sport und Gesundheit in Prävention und Therapie

        • Sportjournalismus

        • Sportmanagement und Sportkommunikation

        • Sport und Leistung

      • Masterstudium

        • Masterstudium

        • M.Sc. Sporttourismus und Destinationsmanagement

        • M.A. Sport-, Medien- und Kommunikationsforschung

        • M.Sc. Sport- und Bewegungstherapie, Prävention und bewegungsbezogene Gesundheitsforschung

        • M.Sc. Leistung, Training und Coaching im Spitzensport

        • M.Sc. Human Technology in Sports and Medicine

        • M.Sc. Psychology in Sport and Exercise

        • M.Sc. Sport Management

        • M.A. International Sport Development and Politics

      • Lehramtsstudium

        • Lehramtsstudium

        • Lehramt an Gymnasien und Gesamtschulen

        • Lehramt an Grundschulen

        • Lehramt an Haupt-, Real-, Sekundar- und Gesamtschulen

        • Lehramt an Berufskollegs

        • Lehramt für sonderpädagogische Förderung

      • Weiterbildendes Master­studium

        • Weiterbildendes Master­studium

        • Führungskompetenz und Management im Spitzensport

          • Führungskompetenz und Management im Spitzensport

          • Voraussetzungen und Bewerbung

        • Olympic Studies

          • Olympic Studies

          • Voraussetzungen und Bewerbung

          • Curriculum & Module

        • M.A. Spielanalyse

          • M.A. Spielanalyse

          • Voraussetzungen und Bewerbung

        • Tanz – Vermittlung, Forschung, künstlerische Praxis

          • Tanz – Vermittlung, Forschung, künstlerische Praxis

          • Zugangsvoraussetzungen, Bewerbung & Gebühren

        • Sport, Bewegung und Ernährung

          • Sport, Bewegung und Ernährung

          • Voraussetzungen und Bewerbung

        • Sportphysiotherapie

          • Sportphysiotherapie

          • Zugangsvoraussetzungen, Bewerbung und Gebühren

        • Schutz vor sexualisierter Gewalt und Machtmissbrauch in Organisationen

      • Campustag

      • Bewerbung

      • Voraussetzungen

        • Voraussetzungen

        • Eignungstest

        • Übetage

      • Immatrikulation

      • Studieren in besonderen Lebenslagen

        • Studieren in besonderen Lebenslagen

        • Studieren mit Kind oder Pflegeaufgaben

        • Studieren mit Behinderung oder chronischer Erkrankung

      • Studium und Spitzensport vereinen

      • Study@GSU

      • Gasthörerschaft

    • Während des Studiums

      • Während des Studiums

      • Veranstaltungen für Studierende

      • Anerkennung und Studiengangswechsel

      • Rückmeldung

      • Exmatrikulation

      • Next Career

    • Nach dem Studium

      • Nach dem Studium

      • Absolvent*innenfeier

      • Career Fitness Program

        • Career Fitness Program

        • Veranstaltungen

      • themenwochen

      • Alumni-Netzwerk

    • Studienstart Bachelor und Lehramt

    • Studienstart Master

    • Weiterbildung

    • In Köln studieren

      • In Köln studieren

      • Studienfinanzierung

        • Studienfinanzierung

        • Deutschlandstipendium

        • NRW-Sportstiftungs-Stipendium

    • Qualität in Studium und Lehre

      • Qualität in Studium und Lehre

      • Qualitätsmanagement

      • Feedback in Studium & Lehre

      • Lehrpreise und Förderprogramme

  • Forschung

    • Forschung

    • Forschungskultur

    • Institute und wissenschaftliche Einrichtungen

    • Wissenschaftliche Laufbahn

      • Wissenschaftliche Laufbahn

      • Promotion

        • Promotion

        • Promotionsstudium

      • Postdocs & Karriereentwicklung

      • Habilitation & Tenure Track

      • Professur

      • Interne Förderprogramme

    • Forschungs­management

      • Forschungs­management

      • Forschungsförderung

      • Forschungsinfrastruktur

      • Forschung international

      • Fit für Forschung und Transfer

      • Studien & Befragungen

        • Studien & Befragungen

        • Teilnehmende für eine Studie mit trans* Personen gesucht

        • Teilnehmende für Long-COVID-Studie gesucht

        • Wissenschaftliche Studie zu Ecdysteron, Muskelaufbau und Kraftentwicklung

        • Wie beeinflussen deine Zyklussymptome deine sportliche Leistungsfähigkeit und Trainingsbeteiligung?

        • Exoskelett-Forschung an der Deutschen Sporthochschule Köln

        • LEAP-Studie

        • Vorhersage der Sauerstoffaufnahme

        • Mechanoprotektive Mechanismen im Skelettmuskel

        • VR-Bewegungstraining

        • Golfen trotz Rückenschmerzen?

        • Relatives Energiedefizit im Sport (REDs)

        • Bewegung, Omega-3 und Curcumin

  • Transfer

    • Transfer

    • Innovationen aus der Forschung

      • Innovationen aus der Forschung

      • Transferberatung & Coaching

      • Transferförderung & Programme

      • Erfindungen, Patente & Schutzrechte

      • Transferprojekte & Initiativen

        • Transferprojekte & Initiativen

        • Sport und Schwangerschaft

        • mentaltalent

        • MentalGestärkt

        • Kinderonko

        • Schulsportlandschaft

          • Schulsportlandschaft

          • Podcast der Schulsportlandschaft

          • Videos & Kurzfilme

          • Tipps für den Schulalltag

          • Forschung, Projekte & Buchtipps

          • Fortbildungen & Veranstaltungen

          • Gimmicks

    • Gründung & Start-ups

      • Gründung & Start-ups

      • Gründungsberatung

      • Angebote & Förderungen

        • Angebote & Förderungen

        • StarS-Kader

        • Gateway EM*power

        • DSHS-Ideathlon

      • Unsere Start-ups

    • Weiterbildungsangebote
Filtern nach
Seiten close Person close News close Event close

4213 Ergebnisse
  • Relevanz
  • Alphabetisch
  • Erstellungsdatum

  • wada_2009_list_modifications.pdf
    1 September 20th, 2008 2009 Prohibited List Summary of Major Modifications and Clarifications INTRODUCTORY PARAGRAPH • Article 4.2.2 of the 2009 Code states: “For purposes of the application of Article 10 (Sanctions on Individuals) all Prohibited Substances shall be ‘Specified Substances’ except substances in the classes of anabolic agents and hormones and those stimulants and hormone antagonists and modulators so identified on the Prohibited List. Prohibited Methods shall not be Specified Substances” To reflect these changes in the Code, the following sentence has been added: “All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4 and S6.a, and Prohibited Methods M1, M2 and M3.” SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) S1. Anabolic Agents 1- Anabolic Androgenic steroids • The nomenclature of prostanozol has been changed to 17β-hydroxy-5α- androstano[3,2-c] pyrazole to better follow the International Union of Pure and Applied Chemistry (IUPAC) rules. • Epitestosterone has been moved from section S5 (Diuretics and other Masking Agents) to S1 (Anabolic Agents, Endogenous Anabolic Androgenic Agents) since it is an isomer of testosterone. This way, epitestosterone will maintain its status as a non-specified substance for sanction purposes. • The detailed explanation on the management of atypical endogenous AAS results has been converted into a comment in accordance with the format of the World Anti-Doping Code. 2 S2. Hormones and Related Substances • In order to reflect the heterogeneity of new EPO-like substances in development, “Erythropoietin” has been replaced by “Erythropoiesis- Stimulating Agents”. • LH, CG clearly named as the Gonadotrophins which are prohibited in males. • The explanatory note at the end of this section has been converted into a comment in accordance with the format of the World Anti-Doping Code. S3. Beta-2 Agonists • In compliance with the 2009 Code, references to Abbreviated TUEs have been removed. • Inhaled formoterol, salbutamol, salmeterol and terbutaline require a Therapeutic Use Exemption in accordance with the new International Standard for Therapeutic Use Exemptions. • The presence of salbutamol in urine in excess of 1000 ng/mL will be considered an Adverse Analytical Finding unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of a therapeutic dose of inhaled salbutamol. A controlled pharmacokinetic study must be conducted in a hospital environment or a reference center for the medical condition concerned, where the administered dose(s) can be rigorously monitored and the quality of the analysis documented. S5. Diuretics and Other masking Agents • As explained above, epitestosterone has been moved to section S1. • Alpha reductase inhibitors are no longer prohibited. They have been rendered ineffective as masking agents by closer consideration of steroid profiles. • The word “intravenous administration” now precedes the examples of plasma expanders albumin, dextran, hydroxyethyl starch, to reflect that these substances are only prohibited when administered by this route; mannitol has been added as an example. Mannitol by inhalation is permitted e.g. to perform bronchial provocation testing in asthma. 3 • It is stated that the carbonic anhydrase inhibitors dorzolamide and brinzolamide, when administered topically in the eye, are not prohibited. The rationale behind this exception is these drugs do not have a diuretic effect when topically applied. PROHIBITED METHODS M2. Chemical and Physical Manipulation • Intravenous infusions are prohibited and thus require a Therapeutic Use Exemption except in the management of surgical procedures, medical emergencies or clinical investigations. The intent of this section is to prohibit hemodilution, overhydration and the administration of prohibited substances by means of intravenous infusion. An intravenous infusion is defined as the delivery of fluids through a vein using a needle or similar device. The legitimate medical uses of intravenous infusions that follow are not prohibited: 1. Emergency intervention including resuscitation; 2. Blood replacement as a consequence of blood loss; 3. Surgical procedures; 4. Administration of drugs and fluids when other routes of administration are not available (e.g. intractable vomiting) in accordance with good medical practice, exclusive of exercise induced dehydration. Injections with a simple syringe are not prohibited as a method if the injected substance is not prohibited and if the volume does not exceed 50 mL. M3. Gene Doping • The definition of Gene Doping has been reworded in order to reflect new technologies in this field. • Peroxisome Proliferator Activated Receptor δ and AMP-activated protein kinase axis agonists have been added based on recent scientific data. 4 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION S6. Stimulants • Based on the article 4.2.2 of the revised Code the List Committee addressed all stimulants named in the 2008 Prohibited List and categorized them as specified or non-specified. The ability to enhance performance in sports, the risk to health, general use in medicinal products, legitimate market availability, their illicit use, legal/controlled status, history and potential of abuse in sports, their metabolism into amphetamine and/or metamphetamine, the likelihood of approval for Therapeutic Use Exemptions, and their pharmacology were taken into consideration. All the non-specified stimulants are named in section S6.a, while a list of examples of specified stimulants are included in section S6.b. • Before considering the reintroduction of pseudoephedrine it was found that more information is needed and a research project is initiated to that effect. As for now, pseudoephedrine remains in the Monitoring Program. S9. Glucocorticosteroids • In compliance with the 2009 Code, references to Abbreviated TUEs have been removed. • In accordance with the International Standard for Therapeutic Use Exemptions, a declaration of use must be completed by the Athlete for the administration of glucocorticosteroids by intraarticular, periarticular, perintendinous, epidural, intradermal and inhalation routes. • No TUE or declaration of use is required for topical administration of glucocorticosteroids SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. Alcohol • The doping violation threshold for blood and breath alcohol (ethanol) has been harmonized for all International Federations to 0.1 g/L. • At the request of the Federation International de Quilleurs (FIQ), Ninepin Bowling is included. WADA List Committee also included Tenpin bowling since this discipline is also part of FIQ. 5 P2. Beta-blockers • At the request of the Federation International de Quilleurs (FIQ), the spelling of Ninepin Bowling is corrected. WADA List Committee also included Tenpin bowling in this category since this discipline is also part of FIQ. • At the request of the International Golf Federation, beta-blockers are now prohibited in golf. SPECIFIED SUBSTANCES • This section is deleted, as the definition of Specified Substances has changed under the revised Code. The new division between Specified and Non-specified Substances is now included in the Introductory Paragraph.

  • wada_2009_list_modifications.pdf
    1 September 20th, 2008 2009 Prohibited List Summary of Major Modifications and Clarifications INTRODUCTORY PARAGRAPH • Article 4.2.2 of the 2009 Code states: “For purposes of the application of Article 10 (Sanctions on Individuals) all Prohibited Substances shall be ‘Specified Substances’ except substances in the classes of anabolic agents and hormones and those stimulants and hormone antagonists and modulators so identified on the Prohibited List. Prohibited Methods shall not be Specified Substances” To reflect these changes in the Code, the following sentence has been added: “All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4 and S6.a, and Prohibited Methods M1, M2 and M3.” SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) S1. Anabolic Agents 1- Anabolic Androgenic steroids • The nomenclature of prostanozol has been changed to 17β-hydroxy-5α- androstano[3,2-c] pyrazole to better follow the International Union of Pure and Applied Chemistry (IUPAC) rules. • Epitestosterone has been moved from section S5 (Diuretics and other Masking Agents) to S1 (Anabolic Agents, Endogenous Anabolic Androgenic Agents) since it is an isomer of testosterone. This way, epitestosterone will maintain its status as a non-specified substance for sanction purposes. • The detailed explanation on the management of atypical endogenous AAS results has been converted into a comment in accordance with the format of the World Anti-Doping Code. 2 S2. Hormones and Related Substances • In order to reflect the heterogeneity of new EPO-like substances in development, “Erythropoietin” has been replaced by “Erythropoiesis- Stimulating Agents”. • LH, CG clearly named as the Gonadotrophins which are prohibited in males. • The explanatory note at the end of this section has been converted into a comment in accordance with the format of the World Anti-Doping Code. S3. Beta-2 Agonists • In compliance with the 2009 Code, references to Abbreviated TUEs have been removed. • Inhaled formoterol, salbutamol, salmeterol and terbutaline require a Therapeutic Use Exemption in accordance with the new International Standard for Therapeutic Use Exemptions. • The presence of salbutamol in urine in excess of 1000 ng/mL will be considered an Adverse Analytical Finding unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of a therapeutic dose of inhaled salbutamol. A controlled pharmacokinetic study must be conducted in a hospital environment or a reference center for the medical condition concerned, where the administered dose(s) can be rigorously monitored and the quality of the analysis documented. S5. Diuretics and Other masking Agents • As explained above, epitestosterone has been moved to section S1. • Alpha reductase inhibitors are no longer prohibited. They have been rendered ineffective as masking agents by closer consideration of steroid profiles. • The word “intravenous administration” now precedes the examples of plasma expanders albumin, dextran, hydroxyethyl starch, to reflect that these substances are only prohibited when administered by this route; mannitol has been added as an example. Mannitol by inhalation is permitted e.g. to perform bronchial provocation testing in asthma. 3 • It is stated that the carbonic anhydrase inhibitors dorzolamide and brinzolamide, when administered topically in the eye, are not prohibited. The rationale behind this exception is these drugs do not have a diuretic effect when topically applied. PROHIBITED METHODS M2. Chemical and Physical Manipulation • Intravenous infusions are prohibited and thus require a Therapeutic Use Exemption except in the management of surgical procedures, medical emergencies or clinical investigations. The intent of this section is to prohibit hemodilution, overhydration and the administration of prohibited substances by means of intravenous infusion. An intravenous infusion is defined as the delivery of fluids through a vein using a needle or similar device. The legitimate medical uses of intravenous infusions that follow are not prohibited: 1. Emergency intervention including resuscitation; 2. Blood replacement as a consequence of blood loss; 3. Surgical procedures; 4. Administration of drugs and fluids when other routes of administration are not available (e.g. intractable vomiting) in accordance with good medical practice, exclusive of exercise induced dehydration. Injections with a simple syringe are not prohibited as a method if the injected substance is not prohibited and if the volume does not exceed 50 mL. M3. Gene Doping • The definition of Gene Doping has been reworded in order to reflect new technologies in this field. • Peroxisome Proliferator Activated Receptor δ and AMP-activated protein kinase axis agonists have been added based on recent scientific data. 4 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION S6. Stimulants • Based on the article 4.2.2 of the revised Code the List Committee addressed all stimulants named in the 2008 Prohibited List and categorized them as specified or non-specified. The ability to enhance performance in sports, the risk to health, general use in medicinal products, legitimate market availability, their illicit use, legal/controlled status, history and potential of abuse in sports, their metabolism into amphetamine and/or metamphetamine, the likelihood of approval for Therapeutic Use Exemptions, and their pharmacology were taken into consideration. All the non-specified stimulants are named in section S6.a, while a list of examples of specified stimulants are included in section S6.b. • Before considering the reintroduction of pseudoephedrine it was found that more information is needed and a research project is initiated to that effect. As for now, pseudoephedrine remains in the Monitoring Program. S9. Glucocorticosteroids • In compliance with the 2009 Code, references to Abbreviated TUEs have been removed. • In accordance with the International Standard for Therapeutic Use Exemptions, a declaration of use must be completed by the Athlete for the administration of glucocorticosteroids by intraarticular, periarticular, perintendinous, epidural, intradermal and inhalation routes. • No TUE or declaration of use is required for topical administration of glucocorticosteroids SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. Alcohol • The doping violation threshold for blood and breath alcohol (ethanol) has been harmonized for all International Federations to 0.1 g/L. • At the request of the Federation International de Quilleurs (FIQ), Ninepin Bowling is included. WADA List Committee also included Tenpin bowling since this discipline is also part of FIQ. 5 P2. Beta-blockers • At the request of the Federation International de Quilleurs (FIQ), the spelling of Ninepin Bowling is corrected. WADA List Committee also included Tenpin bowling in this category since this discipline is also part of FIQ. • At the request of the International Golf Federation, beta-blockers are now prohibited in golf. SPECIFIED SUBSTANCES • This section is deleted, as the definition of Specified Substances has changed under the revised Code. The new division between Specified and Non-specified Substances is now included in the Introductory Paragraph.

  • wada_2008_prohibited_list.pdf
    The World Anti-Doping Code THE 2008 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2008 The Prohibited List 2008 September 22, 2007 THE 2008 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2008 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1- testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltrienolone (17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); methyltestosterone; mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-en-3- one); tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one); The Prohibited List 2008 September 22, 2007 2 trenbolone and other substances with a similar chemical structure or similar biological effect(s). b. Endogenous** AAS: androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene- 3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one) ; prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites and isomers: 5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane- 3β,17α-diol; 5α-androstane-3β,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene- 3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; 4-androstenediol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5- ene-3,17-dione); epi-dihydrotestosterone; 3α-hydroxy-5α-androstan-17- one; 3β-hydroxy-5α-androstan-17-one; 19-norandrosterone; 19- noretiocholanolone. Where an anabolic androgenic steroid is capable of being produced endogenously, a Sample will be deemed to contain such Prohibited Substance and an Adverse Analytical Finding will be reported where the concentration of such Prohibited Substance or its metabolites or markers and/or any other relevant ratio(s) in the Athlete’s Sample so deviates from the range of values normally found in humans that it is unlikely to be consistent with normal endogenous production. A Sample shall not be deemed to contain a Prohibited Substance in any such case where an Athlete proves that the concentration of the Prohibited Substance or its metabolites or markers and/or the relevant ratio(s) in the Athlete’s Sample is attributable to a physiological or pathological condition. In all cases, and at any concentration, the Athlete’s Sample will be deemed to contain a Prohibited Substance and the laboratory will report an Adverse Analytical Finding if, based on any reliable analytical method (e.g. IRMS), the laboratory can show that the Prohibited Substance is of exogenous origin. In such case, no further investigation is necessary. When a value does not so deviate from the range of values normally found in humans and any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, but if there are indications, such as a comparison to endogenous reference steroid profiles, of a possible Use of a Prohibited Substance, or when a laboratory has reported a T/E ratio greater than four (4) to one (1) and any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, further investigation shall be conducted by the relevant Anti-Doping Organization by reviewing the results of any previous test(s) or by conducting subsequent test(s). When such further investigation is required the result shall be reported by the laboratory as atypical and not as adverse. If a laboratory reports, using an The Prohibited List 2008 September 22, 2007 3 additional reliable analytical method (e.g. IRMS), that the Prohibited Substance is of exogenous origin, no further investigation is necessary, and the Sample will be deemed to contain such Prohibited Substance. When an additional reliable analytical method (e.g. IRMS) has not been applied, and the minimum of three previous test results are not available, a longitudinal profile of the Athlete shall be established by performing three no-advance notice tests in a period of three months by the relevant Anti-Doping Organization. The result that triggered this longitudinal study shall be reported as atypical. If the longitudinal profile of the Athlete established by the subsequent tests is not physiologically normal, the result shall then be reported as an Adverse Analytical Finding. In extremely rare individual cases, boldenone of endogenous origin can be consistently found at very low nanograms per milliliter (ng/mL) levels in urine. When such a very low concentration of boldenone is reported by a laboratory and the application of any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, further investigation may be conducted by subsequent test(s). For 19-norandrosterone, an Adverse Analytical Finding reported by a laboratory is considered to be scientific and valid proof of exogenous origin of the Prohibited Substance. In such case, no further investigation is necessary. Should an Athlete fail to cooperate in the investigations, the Athlete’s Sample shall be deemed to contain a Prohibited Substance. 2. Other Anabolic Agents, including but not limited to: Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol. For purposes of this section: * “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally. ** “endogenous” refers to a substance which is capable of being produced by the body naturally. S2. HORMONES AND RELATED SUBSTANCES The following substances and their releasing factors, are prohibited: 1. Erythropoietin (EPO); 2. Growth Hormone (hGH), Insulin-like Growth Factors (e.g. IGF-1), Mechano Growth Factors (MGFs); 3. Gonadotrophins (e.g. LH, hCG), prohibited in males only; 4. Insulins; 5. Corticotrophins. The Prohibited List 2008 September 22, 2007 4 and other substances with similar chemical structure or similar biological effect(s). Unless the Athlete can demonstrate that the concentration was due to a physiological or pathological condition, a Sample will be deemed to contain a Prohibited Substance (as listed above) where the concentration of the Prohibited Substance or its metabolites and/or relevant ratios or markers in the Athlete’s Sample so exceeds the range of values normally found in humans that it is unlikely to be consistent with normal endogenous production. If a laboratory reports, using a reliable analytical method, that the Prohibited Substance is of exogenous origin, the Sample will be deemed to contain a Prohibited Substance and shall be reported as an Adverse Analytical Finding. S3. BETA-2 AGONISTS All beta-2 agonists including their D- and L-isomers are prohibited. As an exception, formoterol, salbutamol, salmeterol and terbutaline when administered by inhalation, require an abbreviated Therapeutic Use Exemption. Despite the granting of any form of Therapeutic Use Exemption, a concentration of salbutamol (free plus glucuronide) greater than 1000 ng/mL will be considered an Adverse Analytical Finding unless the Athlete proves that the abnormal result was the consequence of the therapeutic use of inhaled salbutamol. S4. HORMONE ANTAGONISTS AND MODULATORS The following classes are prohibited: 1. Aromatase inhibitors including, but not limited to: anastrozole, letrozole, aminoglutethimide, exemestane, formestane, testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene. 3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant. 4. Agents modifying myostatin function(s) including but not limited to: myostatin inhibitors. The Prohibited List 2008 September 22, 2007 5 S5. DIURETICS AND OTHER MASKING AGENTS Masking agents are prohibited. They include: Diuretics*, epitestosterone, probenecid, alpha-reductase inhibitors (e.g. finasteride, dutasteride), plasma expanders (e.g. albumin, dextran, hydroxyethyl starch) and other substances with similar biological effect(s). Diuretics include: Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances with a similar chemical structure or similar biological effect(s) (except for drosperinone, which is not prohibited). * A Therapeutic Use Exemption is not valid if an Athlete’s urine contains a diuretic in association with threshold or sub-threshold levels of a Prohibited Substance(s). The Prohibited List 2008 September 22, 2007 6 PROHIBITED METHODS M1. ENHANCEMENT OF OXYGEN TRANSFER The following are prohibited: 1. Blood doping, including the use of autologous, homologous or heterologous blood or red blood cell products of any origin. 2. Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products). M2. CHEMICAL AND PHYSICAL MANIPULATION 1. Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Controls is prohibited. These include but are not limited to catheterisation, urine substitution and/or alteration. 2. Intravenous infusion is prohibited. In an acute medical situation where this method is deemed necessary, a retroactive Therapeutic Use Exemption will be required. M3. GENE DOPING The non-therapeutic use of cells, genes, genetic elements, or of the modulation of gene expression, having the capacity to enhance athletic performance, is prohibited. The Prohibited List 2008 September 22, 2007 7 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the categories S1 to S5 and M1 to M3 defined above, the following categories are prohibited in competition: PROHIBITED SUBSTANCES S6. STIMULANTS All stimulants (including both their (D- & L-) optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2008 Monitoring Program*. Stimulants include: Adrafinil, adrenaline**, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, benzylpiperazine, bromantan, cathine***, clobenzorex, cocaine, cropropamide, crotetamide, cyclazodone, dimethylamphetamine, ephedrine****, etamivan, etilamphetamine, etilefrine, famprofazone, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine, fenproporex, furfenorex, heptaminol, isometheptene, levmethamfetamine, meclofenoxate, mefenorex, mephentermine, mesocarb, methamphetamine (D-), methylenedioxyamphetamine, methylenedioxymethamphetamine, p- methylamphetamine, methylephedrine****, methylphenidate, modafinil, nikethamide, norfenefrine, norfenfluramine, octopamine, ortetamine, oxilofrine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phenmetrazine, phenpromethamine, phentermine, 4- phenylpiracetam (carphedon), prolintane, propylhexedrine, selegiline, sibutramine, strychnine, tuaminoheptane and other substances with a similar chemical structure or similar biological effect(s). * The following substances included in the 2008 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol, pseudoephedrine, synephrine) are not considered as Prohibited Substances. ** Adrenaline associated with local anaesthetic agents or by local administration (e.g. nasal, ophthalmologic) is not prohibited. *** Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter. **** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter. The Prohibited List 2008 September 22, 2007 8 A stimulant not expressly mentioned as an example under this section should be considered as a Specified Substance only if the Athlete can establish that the substance is particularly susceptible to unintentional anti-doping rule violations because of its general availability in medicinal products or is less likely to be successfully abused as a doping agent. S7. NARCOTICS The following narcotics are prohibited: Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine. S8. CANNABINOIDS Cannabinoids (e.g. hashish, marijuana) are prohibited. S9. GLUCOCORTICOSTEROIDS All glucocorticosteroids are prohibited when administered orally, rectally, intravenously or intramuscularly. Their use requires a Therapeutic Use Exemption approval. Other routes of administration (intraarticular /periarticular/ peritendinous/ epidural/ intradermal injections and inhalation) require an Abbreviated Therapeutic Use Exemption except as noted below. Topical preparations when used for dermatological (including iontophoresis/phonophoresis), auricular, nasal, ophthalmic, buccal, gingival and perianal disorders are not prohibited and do not require any form of Therapeutic Use Exemption. The Prohibited List 2008 September 22, 2007 9 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. ALCOHOL Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) for each Federation is reported in parenthesis. • Aeronautic (FAI) (0.20 g/L) • Archery (FITA, IPC) (0.10 g/L) • Automobile (FIA) (0.10 g/L) • Boules (IPC bowls) (0.10 g/L) • Karate (WKF) (0.10 g/L) • Modern Pentathlon (UIPM) (0.10 g/L) for disciplines involving shooting • Motorcycling (FIM) (0.10 g/L) • Powerboating (UIM) (0.30 g/L) P2. BETA-BLOCKERS Unless otherwise specified, beta-blockers are prohibited In-Competition only, in the following sports. • Aeronautic (FAI) • Archery (FITA, IPC) (also prohibited Out-of-Competition) • Automobile (FIA) • Billiards (WCBS) • Bobsleigh (FIBT) • Boules (CMSB, IPC bowls) • Bridge (FMB) • Curling (WCF) • Gymnastics (FIG) • Motorcycling (FIM) • Modern Pentathlon (UIPM) for disciplines involving shooting • Nine-pin bowling (FIQ) • Powerboating (UIM) • Sailing (ISAF) for match race helms only • Shooting (ISSF, IPC) (also prohibited Out-of-Competition) • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Wrestling (FILA) Beta-blockers include, but are not limited to, the following: Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol. The Prohibited List 2008 September 22, 2007 10 SPECIFIED SUBSTANCES* “Specified Substances”* are listed below: • All inhaled Beta-2 Agonists, except salbutamol (free plus glucuronide) greater than 1000 ng/mL and clenbuterol (listed under S1.2: Other Anabolic Agents); • Alpha-reductase inhibitors, probenecid; • Cathine, cropropamide, crotetamide, ephedrine, etamivan, famprofazone, heptaminol, isometheptene, levmethamfetamine, meclofenoxate, p-methylamphetamine, methylephedrine, nikethamide, norfenefrine, octopamine, ortetamine, oxilofrine, phenpromethamine, propylhexedrine, selegiline, sibutramine, tuaminoheptane, and any other stimulant not expressly listed under section S6 for which the Athlete establishes that it fulfils the conditions described in section S6; • Cannabinoids; • All Glucocorticosteroids; • Alcohol; • All Beta Blockers. * “The Prohibited List may identify specified substances which are particularly susceptible to unintentional anti-doping rule violations because of their general availability in medicinal products or which are less likely to be successfully abused as doping agents.” A doping violation involving such substances may result in a reduced sanction provided that the “…Athlete can establish that the Use of such a specified substance was not intended to enhance sport performance…” The Prohibited List 2008 11 September 22, 2007 THE 2008 PROHIBITED LIST All inhaled Beta-2 Agonists, except salbutamol (free plus glucuronide) greater than 1000 ng/mL and clenbuterol (listed under S1.2: Other Anabolic Agents); Alpha-reductase inhibitors, probenecid; p-methylamphetamine, methylephedrine, nikethamide, norfenefrine, octopamine, ortetamine, oxilofrine, phenpromethamine, propylhexedrine, selegiline, sibutramine, tuaminoheptane, and any other stimulant not expressly listed under section S6 for which the Athlete establishes that it fulfils the conditions described in section S6; Cannabinoids; Alcohol; All Beta Blockers.

  • wada_2008_prohibited_list.pdf
    The World Anti-Doping Code THE 2008 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2008 The Prohibited List 2008 September 22, 2007 THE 2008 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2008 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1- testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltrienolone (17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); methyltestosterone; mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-en-3- one); tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one); The Prohibited List 2008 September 22, 2007 2 trenbolone and other substances with a similar chemical structure or similar biological effect(s). b. Endogenous** AAS: androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene- 3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one) ; prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites and isomers: 5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane- 3β,17α-diol; 5α-androstane-3β,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene- 3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; 4-androstenediol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5- ene-3,17-dione); epi-dihydrotestosterone; 3α-hydroxy-5α-androstan-17- one; 3β-hydroxy-5α-androstan-17-one; 19-norandrosterone; 19- noretiocholanolone. Where an anabolic androgenic steroid is capable of being produced endogenously, a Sample will be deemed to contain such Prohibited Substance and an Adverse Analytical Finding will be reported where the concentration of such Prohibited Substance or its metabolites or markers and/or any other relevant ratio(s) in the Athlete’s Sample so deviates from the range of values normally found in humans that it is unlikely to be consistent with normal endogenous production. A Sample shall not be deemed to contain a Prohibited Substance in any such case where an Athlete proves that the concentration of the Prohibited Substance or its metabolites or markers and/or the relevant ratio(s) in the Athlete’s Sample is attributable to a physiological or pathological condition. In all cases, and at any concentration, the Athlete’s Sample will be deemed to contain a Prohibited Substance and the laboratory will report an Adverse Analytical Finding if, based on any reliable analytical method (e.g. IRMS), the laboratory can show that the Prohibited Substance is of exogenous origin. In such case, no further investigation is necessary. When a value does not so deviate from the range of values normally found in humans and any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, but if there are indications, such as a comparison to endogenous reference steroid profiles, of a possible Use of a Prohibited Substance, or when a laboratory has reported a T/E ratio greater than four (4) to one (1) and any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, further investigation shall be conducted by the relevant Anti-Doping Organization by reviewing the results of any previous test(s) or by conducting subsequent test(s). When such further investigation is required the result shall be reported by the laboratory as atypical and not as adverse. If a laboratory reports, using an The Prohibited List 2008 September 22, 2007 3 additional reliable analytical method (e.g. IRMS), that the Prohibited Substance is of exogenous origin, no further investigation is necessary, and the Sample will be deemed to contain such Prohibited Substance. When an additional reliable analytical method (e.g. IRMS) has not been applied, and the minimum of three previous test results are not available, a longitudinal profile of the Athlete shall be established by performing three no-advance notice tests in a period of three months by the relevant Anti-Doping Organization. The result that triggered this longitudinal study shall be reported as atypical. If the longitudinal profile of the Athlete established by the subsequent tests is not physiologically normal, the result shall then be reported as an Adverse Analytical Finding. In extremely rare individual cases, boldenone of endogenous origin can be consistently found at very low nanograms per milliliter (ng/mL) levels in urine. When such a very low concentration of boldenone is reported by a laboratory and the application of any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, further investigation may be conducted by subsequent test(s). For 19-norandrosterone, an Adverse Analytical Finding reported by a laboratory is considered to be scientific and valid proof of exogenous origin of the Prohibited Substance. In such case, no further investigation is necessary. Should an Athlete fail to cooperate in the investigations, the Athlete’s Sample shall be deemed to contain a Prohibited Substance. 2. Other Anabolic Agents, including but not limited to: Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol. For purposes of this section: * “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally. ** “endogenous” refers to a substance which is capable of being produced by the body naturally. S2. HORMONES AND RELATED SUBSTANCES The following substances and their releasing factors, are prohibited: 1. Erythropoietin (EPO); 2. Growth Hormone (hGH), Insulin-like Growth Factors (e.g. IGF-1), Mechano Growth Factors (MGFs); 3. Gonadotrophins (e.g. LH, hCG), prohibited in males only; 4. Insulins; 5. Corticotrophins. The Prohibited List 2008 September 22, 2007 4 and other substances with similar chemical structure or similar biological effect(s). Unless the Athlete can demonstrate that the concentration was due to a physiological or pathological condition, a Sample will be deemed to contain a Prohibited Substance (as listed above) where the concentration of the Prohibited Substance or its metabolites and/or relevant ratios or markers in the Athlete’s Sample so exceeds the range of values normally found in humans that it is unlikely to be consistent with normal endogenous production. If a laboratory reports, using a reliable analytical method, that the Prohibited Substance is of exogenous origin, the Sample will be deemed to contain a Prohibited Substance and shall be reported as an Adverse Analytical Finding. S3. BETA-2 AGONISTS All beta-2 agonists including their D- and L-isomers are prohibited. As an exception, formoterol, salbutamol, salmeterol and terbutaline when administered by inhalation, require an abbreviated Therapeutic Use Exemption. Despite the granting of any form of Therapeutic Use Exemption, a concentration of salbutamol (free plus glucuronide) greater than 1000 ng/mL will be considered an Adverse Analytical Finding unless the Athlete proves that the abnormal result was the consequence of the therapeutic use of inhaled salbutamol. S4. HORMONE ANTAGONISTS AND MODULATORS The following classes are prohibited: 1. Aromatase inhibitors including, but not limited to: anastrozole, letrozole, aminoglutethimide, exemestane, formestane, testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene. 3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant. 4. Agents modifying myostatin function(s) including but not limited to: myostatin inhibitors. The Prohibited List 2008 September 22, 2007 5 S5. DIURETICS AND OTHER MASKING AGENTS Masking agents are prohibited. They include: Diuretics*, epitestosterone, probenecid, alpha-reductase inhibitors (e.g. finasteride, dutasteride), plasma expanders (e.g. albumin, dextran, hydroxyethyl starch) and other substances with similar biological effect(s). Diuretics include: Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances with a similar chemical structure or similar biological effect(s) (except for drosperinone, which is not prohibited). * A Therapeutic Use Exemption is not valid if an Athlete’s urine contains a diuretic in association with threshold or sub-threshold levels of a Prohibited Substance(s). The Prohibited List 2008 September 22, 2007 6 PROHIBITED METHODS M1. ENHANCEMENT OF OXYGEN TRANSFER The following are prohibited: 1. Blood doping, including the use of autologous, homologous or heterologous blood or red blood cell products of any origin. 2. Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products). M2. CHEMICAL AND PHYSICAL MANIPULATION 1. Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Controls is prohibited. These include but are not limited to catheterisation, urine substitution and/or alteration. 2. Intravenous infusion is prohibited. In an acute medical situation where this method is deemed necessary, a retroactive Therapeutic Use Exemption will be required. M3. GENE DOPING The non-therapeutic use of cells, genes, genetic elements, or of the modulation of gene expression, having the capacity to enhance athletic performance, is prohibited. The Prohibited List 2008 September 22, 2007 7 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the categories S1 to S5 and M1 to M3 defined above, the following categories are prohibited in competition: PROHIBITED SUBSTANCES S6. STIMULANTS All stimulants (including both their (D- & L-) optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2008 Monitoring Program*. Stimulants include: Adrafinil, adrenaline**, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, benzylpiperazine, bromantan, cathine***, clobenzorex, cocaine, cropropamide, crotetamide, cyclazodone, dimethylamphetamine, ephedrine****, etamivan, etilamphetamine, etilefrine, famprofazone, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine, fenproporex, furfenorex, heptaminol, isometheptene, levmethamfetamine, meclofenoxate, mefenorex, mephentermine, mesocarb, methamphetamine (D-), methylenedioxyamphetamine, methylenedioxymethamphetamine, p- methylamphetamine, methylephedrine****, methylphenidate, modafinil, nikethamide, norfenefrine, norfenfluramine, octopamine, ortetamine, oxilofrine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phenmetrazine, phenpromethamine, phentermine, 4- phenylpiracetam (carphedon), prolintane, propylhexedrine, selegiline, sibutramine, strychnine, tuaminoheptane and other substances with a similar chemical structure or similar biological effect(s). * The following substances included in the 2008 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol, pseudoephedrine, synephrine) are not considered as Prohibited Substances. ** Adrenaline associated with local anaesthetic agents or by local administration (e.g. nasal, ophthalmologic) is not prohibited. *** Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter. **** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter. The Prohibited List 2008 September 22, 2007 8 A stimulant not expressly mentioned as an example under this section should be considered as a Specified Substance only if the Athlete can establish that the substance is particularly susceptible to unintentional anti-doping rule violations because of its general availability in medicinal products or is less likely to be successfully abused as a doping agent. S7. NARCOTICS The following narcotics are prohibited: Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine. S8. CANNABINOIDS Cannabinoids (e.g. hashish, marijuana) are prohibited. S9. GLUCOCORTICOSTEROIDS All glucocorticosteroids are prohibited when administered orally, rectally, intravenously or intramuscularly. Their use requires a Therapeutic Use Exemption approval. Other routes of administration (intraarticular /periarticular/ peritendinous/ epidural/ intradermal injections and inhalation) require an Abbreviated Therapeutic Use Exemption except as noted below. Topical preparations when used for dermatological (including iontophoresis/phonophoresis), auricular, nasal, ophthalmic, buccal, gingival and perianal disorders are not prohibited and do not require any form of Therapeutic Use Exemption. The Prohibited List 2008 September 22, 2007 9 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. ALCOHOL Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) for each Federation is reported in parenthesis. • Aeronautic (FAI) (0.20 g/L) • Archery (FITA, IPC) (0.10 g/L) • Automobile (FIA) (0.10 g/L) • Boules (IPC bowls) (0.10 g/L) • Karate (WKF) (0.10 g/L) • Modern Pentathlon (UIPM) (0.10 g/L) for disciplines involving shooting • Motorcycling (FIM) (0.10 g/L) • Powerboating (UIM) (0.30 g/L) P2. BETA-BLOCKERS Unless otherwise specified, beta-blockers are prohibited In-Competition only, in the following sports. • Aeronautic (FAI) • Archery (FITA, IPC) (also prohibited Out-of-Competition) • Automobile (FIA) • Billiards (WCBS) • Bobsleigh (FIBT) • Boules (CMSB, IPC bowls) • Bridge (FMB) • Curling (WCF) • Gymnastics (FIG) • Motorcycling (FIM) • Modern Pentathlon (UIPM) for disciplines involving shooting • Nine-pin bowling (FIQ) • Powerboating (UIM) • Sailing (ISAF) for match race helms only • Shooting (ISSF, IPC) (also prohibited Out-of-Competition) • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Wrestling (FILA) Beta-blockers include, but are not limited to, the following: Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol. The Prohibited List 2008 September 22, 2007 10 SPECIFIED SUBSTANCES* “Specified Substances”* are listed below: • All inhaled Beta-2 Agonists, except salbutamol (free plus glucuronide) greater than 1000 ng/mL and clenbuterol (listed under S1.2: Other Anabolic Agents); • Alpha-reductase inhibitors, probenecid; • Cathine, cropropamide, crotetamide, ephedrine, etamivan, famprofazone, heptaminol, isometheptene, levmethamfetamine, meclofenoxate, p-methylamphetamine, methylephedrine, nikethamide, norfenefrine, octopamine, ortetamine, oxilofrine, phenpromethamine, propylhexedrine, selegiline, sibutramine, tuaminoheptane, and any other stimulant not expressly listed under section S6 for which the Athlete establishes that it fulfils the conditions described in section S6; • Cannabinoids; • All Glucocorticosteroids; • Alcohol; • All Beta Blockers. * “The Prohibited List may identify specified substances which are particularly susceptible to unintentional anti-doping rule violations because of their general availability in medicinal products or which are less likely to be successfully abused as doping agents.” A doping violation involving such substances may result in a reduced sanction provided that the “…Athlete can establish that the Use of such a specified substance was not intended to enhance sport performance…” The Prohibited List 2008 11 September 22, 2007 THE 2008 PROHIBITED LIST All inhaled Beta-2 Agonists, except salbutamol (free plus glucuronide) greater than 1000 ng/mL and clenbuterol (listed under S1.2: Other Anabolic Agents); Alpha-reductase inhibitors, probenecid; p-methylamphetamine, methylephedrine, nikethamide, norfenefrine, octopamine, ortetamine, oxilofrine, phenpromethamine, propylhexedrine, selegiline, sibutramine, tuaminoheptane, and any other stimulant not expressly listed under section S6 for which the Athlete establishes that it fulfils the conditions described in section S6; Cannabinoids; Alcohol; All Beta Blockers.

  • wada_2008_list_modifications.pdf
    CONFIDENTIAL 1 April 21st, 2007 2008 Prohibited List Summary of Major Modifications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) S1. Anabolic Steroids • The fourth paragraph of the explanatory note has been divided into two parts: 1) In the first part, the first sentence has been expanded to emphasize the notion that abnormal steroid indicators other than the T/E ratio > 4 can also trigger further investigations to determine the origin of an endogenous substance. This is reflected in the phrase "…or other indicators point towards a result that is unlikely to be consistent with normal endogenous production". 2) In the second part, two additional sentences have been added to establish that if an initial result for an endogenous anabolic steroid triggers additional investigations in order to determine the endogenous or exogenous origin of the substance, then the sample should be reported as abnormal instead of an Adverse Analytical Finding. This concept of abnormal result is incorporated as follows: " For testosterone, or any other anabolic androgenic steroid, capable of being produced endogenously, when further investigation is required [e.g. a reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance], the result shall be reported by the laboratory as abnormal and not as adverse." and "The result that triggered this longitudinal study shall be reported as abnormal". S2. Hormones and Related Substances • To be consistent with the presentation of the other sections, the introductory sentence was split in two before and after the list of examples. • It is noted that LH and hCG are just 2 examples of Gonadotrophins by adding “e.g.” CONFIDENTIAL 2 • Myostatin inhibitors are explicitly named as examples of Hormones and related substances. • The last paragraph of the section has been deleted to avoid redundancies with “including other substances with similar chemical structure or similar biological effect(s)”. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION S6. Stimulants • The statuses of pseudoephedrine and cathine have been debated over the last year or more. The WADA List Committee recognizes the analytical problems that arise from the fact that cathine, metabolite of pseudoephedrine (and drug per se) is listed but not the parent compound (pseudoephedrine). To address the issue, three options are being considered. The List Committee recommends option 1. The stakeholders are invited to express their preferred option. The options are as follows: 1) Include cathine in the Monitoring Program. With this option cathine will no longer be considered a Prohibited Substance. 2) Increase the threshold of cathine to 10µg/mL. Higher concentrations will be considered an Adverse Analytical Finding regardless of the presence or absence of pseudoephedrine. 3) Re-instate pseudoephedrine as a Prohibited Substance with a threshold of 100 µg/mL, while leaving cathine at 5µg/mL. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. Alcohol • At the request of the CMSB (Boules), this Federation is removed from this section. SPECIFIED SUBSTANCES • It is clarified that the beta-2-agonist clenbuterol is listed in the S1.2 section as Other Anabolic Agents. Summary of Major Modifications

  • wada_2008_list_modifications.pdf
    CONFIDENTIAL 1 April 21st, 2007 2008 Prohibited List Summary of Major Modifications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) S1. Anabolic Steroids • The fourth paragraph of the explanatory note has been divided into two parts: 1) In the first part, the first sentence has been expanded to emphasize the notion that abnormal steroid indicators other than the T/E ratio > 4 can also trigger further investigations to determine the origin of an endogenous substance. This is reflected in the phrase "…or other indicators point towards a result that is unlikely to be consistent with normal endogenous production". 2) In the second part, two additional sentences have been added to establish that if an initial result for an endogenous anabolic steroid triggers additional investigations in order to determine the endogenous or exogenous origin of the substance, then the sample should be reported as abnormal instead of an Adverse Analytical Finding. This concept of abnormal result is incorporated as follows: " For testosterone, or any other anabolic androgenic steroid, capable of being produced endogenously, when further investigation is required [e.g. a reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance], the result shall be reported by the laboratory as abnormal and not as adverse." and "The result that triggered this longitudinal study shall be reported as abnormal". S2. Hormones and Related Substances • To be consistent with the presentation of the other sections, the introductory sentence was split in two before and after the list of examples. • It is noted that LH and hCG are just 2 examples of Gonadotrophins by adding “e.g.” CONFIDENTIAL 2 • Myostatin inhibitors are explicitly named as examples of Hormones and related substances. • The last paragraph of the section has been deleted to avoid redundancies with “including other substances with similar chemical structure or similar biological effect(s)”. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION S6. Stimulants • The statuses of pseudoephedrine and cathine have been debated over the last year or more. The WADA List Committee recognizes the analytical problems that arise from the fact that cathine, metabolite of pseudoephedrine (and drug per se) is listed but not the parent compound (pseudoephedrine). To address the issue, three options are being considered. The List Committee recommends option 1. The stakeholders are invited to express their preferred option. The options are as follows: 1) Include cathine in the Monitoring Program. With this option cathine will no longer be considered a Prohibited Substance. 2) Increase the threshold of cathine to 10µg/mL. Higher concentrations will be considered an Adverse Analytical Finding regardless of the presence or absence of pseudoephedrine. 3) Re-instate pseudoephedrine as a Prohibited Substance with a threshold of 100 µg/mL, while leaving cathine at 5µg/mL. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. Alcohol • At the request of the CMSB (Boules), this Federation is removed from this section. SPECIFIED SUBSTANCES • It is clarified that the beta-2-agonist clenbuterol is listed in the S1.2 section as Other Anabolic Agents. Summary of Major Modifications

  • wada_2007_prohibited_list.pdf
    September 16, 2006 The World Anti-Doping Code THE 2007 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2007 The Prohibited List 2007 September 16, 2006 2 THE 2007 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2007 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1- testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltrienolone (17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); methyltestosterone; mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-en-3- The Prohibited List 2007 September 16, 2006 3 one); tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one); trenbolone and other substances with a similar chemical structure or similar biological effect(s). b. Endogenous** AAS: androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene- 3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one) ; prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites and isomers: 5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane- 3β,17α-diol; 5α-androstane-3β,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene- 3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; 4-androstenediol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5- ene-3,17-dione); epi-dihydrotestosterone; 3α-hydroxy-5α-androstan-17- one; 3β-hydroxy-5α-androstan-17-one; 19-norandrosterone; 19- noretiocholanolone. Where an anabolic androgenic steroid is capable of being produced endogenously, a Sample will be deemed to contain such Prohibited Substance where the concentration of such Prohibited Substance or its metabolites or markers and/or any other relevant ratio(s) in the Athlete’s Sample so deviates from the range of values normally found in humans that it is unlikely to be consistent with normal endogenous production. A Sample shall not be deemed to contain a Prohibited Substance in any such case where an Athlete proves that the concentration of the Prohibited Substance or its metabolites or markers and/or the relevant ratio(s) in the Athlete’s Sample is attributable to a physiological or pathological condition. In all cases, and at any concentration, the Athlete’s sample will be deemed to contain a Prohibited Substance and the laboratory will report an Adverse Analytical Finding if, based on any reliable analytical method (e.g. IRMS), the laboratory can show that the Prohibited Substance is of exogenous origin. In such case, no further investigation is necessary. If a value in the range of levels normally found in humans is reported and the reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, but if there are indications, such as a comparison to endogenous reference steroid profiles, of a possible Use of a Prohibited Substance, further investigation shall be conducted by the relevant Anti-Doping Organization by reviewing the results of any previous test(s) or by conducting subsequent test(s), in order to determine whether the result is due to a physiological or pathological condition, or has occurred as a consequence of the exogenous origin of a Prohibited Substance. The Prohibited List 2007 September 16, 2006 4 When a laboratory has reported a T/E ratio greater than four (4) to one (1) and any reliable analytical method (e.g. IRMS) applied has not determined the exogenous origin of the substance, further investigation may be conducted by a review of previous tests or by conducting subsequent test(s), in order to determine whether the result is due to a physiological or pathological condition, or has occurred as a consequence of the exogenous origin of a Prohibited Substance. If a laboratory reports, using an additional reliable analytical method (e.g. IRMS), that the Prohibited Substance is of exogenous origin, no further investigation is necessary and the Sample will be deemed to contain such Prohibited Substance. When an additional reliable analytical method (e.g. IRMS) has not been applied and a minimum of three previous test results are not available, a longitudinal profile of the Athlete shall be established by performing a minimum of three no advance notice tests in a period of three months by the relevant Anti-Doping Organization. If the longitudinal profile of the Athlete established by the subsequent tests is not physiologically normal, the result shall be reported as an Adverse Analytical Finding. In extremely rare individual cases, boldenone of endogenous origin can be consistently found at very low nanograms per milliliter (ng/mL) levels in urine. When such a very low concentration of boldenone is reported by a laboratory and the application of any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, further investigation may be conducted by subsequent tests. When an additional reliable analytical method (e.g. IRMS) has not been applied, a longitudinal profile of the athlete shall be established by performing a minimum of three no advance notice tests in a period of three months by the relevant Anti-Doping Organization. If the longitudinal profile of the Athlete established by the subsequent tests is not physiologically normal, the result shall be reported as an Adverse Analytical Finding. For 19-norandrosterone, an Adverse Analytical Finding reported by a laboratory is considered to be scientific and valid proof of exogenous origin of the Prohibited Substance. In such case, no further investigation is necessary. Should an Athlete fail to cooperate in the investigations, the Athlete’s Sample shall be deemed to contain a Prohibited Substance. 2. Other Anabolic Agents, including but not limited to: Clenbuterol, tibolone, zeranol, zilpaterol. For purposes of this section: * “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally. ** “endogenous” refers to a substance which is capable of being produced by the body naturally. The Prohibited List 2007 September 16, 2006 5 S2. HORMONES AND RELATED SUBSTANCES The following substances, including other substances with a similar chemical structure or similar biological effect(s), and their releasing factors, are prohibited: 1. Erythropoietin (EPO); 2. Growth Hormone (hGH), Insulin-like Growth Factors (e.g. IGF-1), Mechano Growth Factors (MGFs); 3. Gonadotrophins (LH, hCG), prohibited in males only; 4. Insulin; 5. Corticotrophins. Unless the Athlete can demonstrate that the concentration was due to a physiological or pathological condition, a Sample will be deemed to contain a Prohibited Substance (as listed above) where the concentration of the Prohibited Substance or its metabolites and/or relevant ratios or markers in the Athlete’s Sample so exceeds the range of values normally found in humans that it is unlikely to be consistent with normal endogenous production. If a laboratory reports, using a reliable analytical method, that the Prohibited Substance is of exogenous origin, the Sample will be deemed to contain a Prohibited Substance and shall be reported as an Adverse Analytical Finding. The presence of other substances with a similar chemical structure or similar biological effect(s), diagnostic marker(s) or releasing factors of a hormone listed above or of any other finding which indicate(s) that the substance detected is of exogenous origin, will be deemed to reflect the use of a Prohibited Substance and shall be reported as an Adverse Analytical Finding. S3. BETA-2 AGONISTS All beta-2 agonists including their D- and L-isomers are prohibited. As an exception, formoterol, salbutamol, salmeterol and terbutaline when administered by inhalation, require an abbreviated Therapeutic Use Exemption. Despite the granting of any form of Therapeutic Use Exemption, a concentration of salbutamol (free plus glucuronide) greater than 1000 ng/mL will be considered an Adverse Analytical Finding unless the Athlete proves that the abnormal result was the consequence of the therapeutic use of inhaled salbutamol. The Prohibited List 2007 September 16, 2006 6 S4. AGENTS WITH ANTI-ESTROGENIC ACTIVITY The following classes of anti-estrogenic substances are prohibited: 1. Aromatase inhibitors including, but not limited to, anastrozole, letrozole, aminoglutethimide, exemestane, formestane, testolactone. 2. Selective Estrogen Receptor Modulators (SERMs) including, but not limited to, raloxifene, tamoxifen, toremifene. 3. Other anti-estrogenic substances including, but not limited to, clomiphene, cyclofenil, fulvestrant. S5. DIURETICS AND OTHER MASKING AGENTS Masking agents are prohibited. They include: Diuretics*, epitestosterone, probenecid, alpha-reductase inhibitors (e.g. finasteride, dutasteride), plasma expanders (e.g. albumin, dextran, hydroxyethyl starch) and other substances with similar biological effect(s). Diuretics include: acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances with a similar chemical structure or similar biological effect(s) (except for drosperinone, which is not prohibited). * A Therapeutic Use Exemption is not valid if an Athlete’s urine contains a diuretic in association with threshold or sub-threshold levels of a Prohibited Substance(s). The Prohibited List 2007 September 16, 2006 7 PROHIBITED METHODS M1. ENHANCEMENT OF OXYGEN TRANSFER The following are prohibited: 1. Blood doping, including the use of autologous, homologous or heterologous blood or red blood cell products of any origin. 2. Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products). M2. CHEMICAL AND PHYSICAL MANIPULATION 1. Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Controls is prohibited. These include but are not limited to catheterisation, urine substitution and/or alteration. 2. Intravenous infusions are prohibited, except as a legitimate medical treatment. M3. GENE DOPING The non-therapeutic use of cells, genes, genetic elements, or of the modulation of gene expression, having the capacity to enhance athletic performance, is prohibited. The Prohibited List 2007 September 16, 2006 8 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the categories S1 to S5 and M1 to M3 defined above, the following categories are prohibited in competition: PROHIBITED SUBSTANCES S6. STIMULANTS All stimulants (including both their (D- & L-) optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2007 Monitoring Program*. Stimulants include: Adrafinil, adrenaline**, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, benzylpiperazine, bromantan, cathine***, clobenzorex, cocaine, cropropamide, crotetamide, cyclazodone, dimethylamphetamine, ephedrine****, etamivan, etilamphetamine, etilefrine, famprofazone, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine, fenproporex, furfenorex, heptaminol, isometheptene, levmethamfetamine, meclofenoxate, mefenorex, mephentermine, mesocarb, methamphetamine (D-), methylenedioxyamphetamine, methylenedioxymethamphetamine, p- methylamphetamine, methylephedrine****, methylphenidate, modafinil, nikethamide, norfenefrine, norfenfluramine, octopamine, ortetamine, oxilofrine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phenmetrazine, phenpromethamine, phentermine, 4- phenylpiracetam (carphedon), prolintane, propylhexedrine, selegiline, sibutramine, strychnine, tuaminoheptane and other substances with a similar chemical structure or similar biological effect(s). * The following substances included in the 2007 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol, pseudoephedrine, synephrine) are not considered as Prohibited Substances. ** Adrenaline associated with local anaesthetic agents or by local administration (e.g. nasal, ophthalmologic) is not prohibited. *** Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter. **** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter. The Prohibited List 2007 September 16, 2006 9 A stimulant not expressly mentioned as an example under this section should be considered as a Specified Substance only if the Athlete can establish that the substance is particularly susceptible to unintentional anti-doping rule violations because of its general availability in medicinal products or is less likely to be successfully abused as a doping agent. S7. NARCOTICS The following narcotics are prohibited: buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine. S8. CANNABINOIDS Cannabinoids (e.g. hashish, marijuana) are prohibited. S9. GLUCOCORTICOSTEROIDS All glucocorticosteroids are prohibited when administered orally, rectally, intravenously or intramuscularly. Their use requires a Therapeutic Use Exemption approval. Other routes of administration (intraarticular /periarticular/ peritendinous/ epidural/ intradermal injections and inhalation) require an Abbreviated Therapeutic Use Exemption except as noted below. Topical preparations when used for dermatological (including iontophoresis/phonophoresis), auricular, nasal, ophthalmic, buccal, gingival and perianal disorders are not prohibited and do not require any form of Therapeutic Use Exemption. The Prohibited List 2007 September 16, 2006 10 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. ALCOHOL Alcohol (ethanol) is prohibited in-competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) for each Federation is reported in parenthesis. • Aeronautic (FAI) (0.20 g/L) • Archery (FITA, IPC) (0.10 g/L) • Automobile (FIA) (0.10 g/L) • Boules (CMSB, (0.10 g/L) IPC bowls) • Karate (WKF) (0.10 g/L) • Modern Pentathlon (UIPM) (0.10 g/L) for disciplines involving shooting • Motorcycling (FIM) (0.10 g/L) • Powerboating (UIM) (0.30 g/L) P2. BETA-BLOCKERS Unless otherwise specified, beta-blockers are prohibited in-competition only, in the following sports. • Aeronautic (FAI) • Archery (FITA, IPC) (also prohibited out-of-competition) • Automobile (FIA) • Billiards (WCBS) • Bobsleigh (FIBT) • Boules (CMSB, IPC bowls) • Bridge (FMB) • Curling (WCF) • Gymnastics (FIG) • Motorcycling (FIM) • Modern Pentathlon (UIPM) for disciplines involving shooting • Nine-pin bowling (FIQ) • Sailing (ISAF) for match race helms only • Shooting (ISSF, IPC) (also prohibited out-of-competition) • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Wrestling (FILA) Beta-blockers include, but are not limited to, the following: acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol. The Prohibited List 2007 11 September 16, 2006 SPECIFIED SUBSTANCES* “Specified Substances”* are listed below: • All inhaled Beta-2 Agonists, except salbutamol (free plus glucuronide) greater than 1000 ng/mL and clenbuterol; • Probenecid; • Cathine, cropropamide, crotetamide, ephedrine, etamivan, famprofazone, heptaminol, isometheptene, levmethamfetamine, meclofenoxate, p-methylamphetamine, methylephedrine, nikethamide, norfenefrine, octopamine, ortetamine, oxilofrine, phenpromethamine, propylhexedrine, selegiline, sibutramine, tuaminoheptane, and any other stimulant not expressly listed under section S6 for which the Athlete establishes that it fulfils the conditions described in section S6; • Cannabinoids; • All Glucocorticosteroids; • Alcohol; • All Beta Blockers. * “The Prohibited List may identify specified substances which are particularly susceptible to unintentional anti-doping rule violations because of their general availability in medicinal products or which are less likely to be successfully abused as doping agents.” A doping violation involving such substances may result in a reduced sanction provided that the “…Athlete can establish that the Use of such a specified substance was not intended to enhance sport performance…” THE 2007 PROHIBITED LIST SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) UAnabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: PROHIBITED METHODS SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the categories S1 to S5 and M1 to M3 defined above, the following categories are prohibited in competition: US6. STIMULANTS US8. CANNABINOIDS US9. GLUCOCORTICOSTEROIDS All glucocorticosteroids are prohibited when administered orally, rectally, intravenously or intramuscularly. Their use requires a Therapeutic Use Exemption approval. Other routes of administration (intraarticular /periarticular/ peritendinous/ epidural/ intradermal injections and inhalation) require an Abbreviated Therapeutic Use Exemption except as noted below. Topical preparations when used for dermatological (including iontophoresis/phonophoresis), auricular, nasal, ophthalmic, buccal, gingival and perianal disorders are not prohibited and do not require any form of Therapeutic Use Exemption. UP1. ALCOHOL Aeronautic (FAI) (0.20 g/L) Archery (FITA, IPC) (0.10 g/L) Automobile (FIA) (0.10 g/L) Boules (CMSB, (0.10 g/L) IPC bowls) Karate (WKF) (0.10 g/L) Modern Pentathlon (UIPM) (0.10 g/L) for disciplines involving shooting Motorcycling (FIM) (0.10 g/L) Powerboating (UIM) (0.30 g/L) UP2. BETA-BLOCKERS All inhaled Beta-2 Agonists, except salbutamol (free plus glucuronide) greater than 1000 ng/mL and clenbuterol; Probenecid; p-methylamphetamine, methylephedrine, nikethamide, norfenefrine, octopamine, ortetamine, oxilofrine, phenpromethamine, propylhexedrine, selegiline, sibutramine, tuaminoheptane, and any other stimulant not expressly listed under section S6 for which th... Cannabinoids; Alcohol; All Beta Blockers.

  • wada_2007_prohibited_list.pdf
    September 16, 2006 The World Anti-Doping Code THE 2007 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2007 The Prohibited List 2007 September 16, 2006 2 THE 2007 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2007 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1- testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltrienolone (17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); methyltestosterone; mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-en-3- The Prohibited List 2007 September 16, 2006 3 one); tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one); trenbolone and other substances with a similar chemical structure or similar biological effect(s). b. Endogenous** AAS: androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene- 3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one) ; prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites and isomers: 5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane- 3β,17α-diol; 5α-androstane-3β,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene- 3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; 4-androstenediol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5- ene-3,17-dione); epi-dihydrotestosterone; 3α-hydroxy-5α-androstan-17- one; 3β-hydroxy-5α-androstan-17-one; 19-norandrosterone; 19- noretiocholanolone. Where an anabolic androgenic steroid is capable of being produced endogenously, a Sample will be deemed to contain such Prohibited Substance where the concentration of such Prohibited Substance or its metabolites or markers and/or any other relevant ratio(s) in the Athlete’s Sample so deviates from the range of values normally found in humans that it is unlikely to be consistent with normal endogenous production. A Sample shall not be deemed to contain a Prohibited Substance in any such case where an Athlete proves that the concentration of the Prohibited Substance or its metabolites or markers and/or the relevant ratio(s) in the Athlete’s Sample is attributable to a physiological or pathological condition. In all cases, and at any concentration, the Athlete’s sample will be deemed to contain a Prohibited Substance and the laboratory will report an Adverse Analytical Finding if, based on any reliable analytical method (e.g. IRMS), the laboratory can show that the Prohibited Substance is of exogenous origin. In such case, no further investigation is necessary. If a value in the range of levels normally found in humans is reported and the reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, but if there are indications, such as a comparison to endogenous reference steroid profiles, of a possible Use of a Prohibited Substance, further investigation shall be conducted by the relevant Anti-Doping Organization by reviewing the results of any previous test(s) or by conducting subsequent test(s), in order to determine whether the result is due to a physiological or pathological condition, or has occurred as a consequence of the exogenous origin of a Prohibited Substance. The Prohibited List 2007 September 16, 2006 4 When a laboratory has reported a T/E ratio greater than four (4) to one (1) and any reliable analytical method (e.g. IRMS) applied has not determined the exogenous origin of the substance, further investigation may be conducted by a review of previous tests or by conducting subsequent test(s), in order to determine whether the result is due to a physiological or pathological condition, or has occurred as a consequence of the exogenous origin of a Prohibited Substance. If a laboratory reports, using an additional reliable analytical method (e.g. IRMS), that the Prohibited Substance is of exogenous origin, no further investigation is necessary and the Sample will be deemed to contain such Prohibited Substance. When an additional reliable analytical method (e.g. IRMS) has not been applied and a minimum of three previous test results are not available, a longitudinal profile of the Athlete shall be established by performing a minimum of three no advance notice tests in a period of three months by the relevant Anti-Doping Organization. If the longitudinal profile of the Athlete established by the subsequent tests is not physiologically normal, the result shall be reported as an Adverse Analytical Finding. In extremely rare individual cases, boldenone of endogenous origin can be consistently found at very low nanograms per milliliter (ng/mL) levels in urine. When such a very low concentration of boldenone is reported by a laboratory and the application of any reliable analytical method (e.g. IRMS) has not determined the exogenous origin of the substance, further investigation may be conducted by subsequent tests. When an additional reliable analytical method (e.g. IRMS) has not been applied, a longitudinal profile of the athlete shall be established by performing a minimum of three no advance notice tests in a period of three months by the relevant Anti-Doping Organization. If the longitudinal profile of the Athlete established by the subsequent tests is not physiologically normal, the result shall be reported as an Adverse Analytical Finding. For 19-norandrosterone, an Adverse Analytical Finding reported by a laboratory is considered to be scientific and valid proof of exogenous origin of the Prohibited Substance. In such case, no further investigation is necessary. Should an Athlete fail to cooperate in the investigations, the Athlete’s Sample shall be deemed to contain a Prohibited Substance. 2. Other Anabolic Agents, including but not limited to: Clenbuterol, tibolone, zeranol, zilpaterol. For purposes of this section: * “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally. ** “endogenous” refers to a substance which is capable of being produced by the body naturally. The Prohibited List 2007 September 16, 2006 5 S2. HORMONES AND RELATED SUBSTANCES The following substances, including other substances with a similar chemical structure or similar biological effect(s), and their releasing factors, are prohibited: 1. Erythropoietin (EPO); 2. Growth Hormone (hGH), Insulin-like Growth Factors (e.g. IGF-1), Mechano Growth Factors (MGFs); 3. Gonadotrophins (LH, hCG), prohibited in males only; 4. Insulin; 5. Corticotrophins. Unless the Athlete can demonstrate that the concentration was due to a physiological or pathological condition, a Sample will be deemed to contain a Prohibited Substance (as listed above) where the concentration of the Prohibited Substance or its metabolites and/or relevant ratios or markers in the Athlete’s Sample so exceeds the range of values normally found in humans that it is unlikely to be consistent with normal endogenous production. If a laboratory reports, using a reliable analytical method, that the Prohibited Substance is of exogenous origin, the Sample will be deemed to contain a Prohibited Substance and shall be reported as an Adverse Analytical Finding. The presence of other substances with a similar chemical structure or similar biological effect(s), diagnostic marker(s) or releasing factors of a hormone listed above or of any other finding which indicate(s) that the substance detected is of exogenous origin, will be deemed to reflect the use of a Prohibited Substance and shall be reported as an Adverse Analytical Finding. S3. BETA-2 AGONISTS All beta-2 agonists including their D- and L-isomers are prohibited. As an exception, formoterol, salbutamol, salmeterol and terbutaline when administered by inhalation, require an abbreviated Therapeutic Use Exemption. Despite the granting of any form of Therapeutic Use Exemption, a concentration of salbutamol (free plus glucuronide) greater than 1000 ng/mL will be considered an Adverse Analytical Finding unless the Athlete proves that the abnormal result was the consequence of the therapeutic use of inhaled salbutamol. The Prohibited List 2007 September 16, 2006 6 S4. AGENTS WITH ANTI-ESTROGENIC ACTIVITY The following classes of anti-estrogenic substances are prohibited: 1. Aromatase inhibitors including, but not limited to, anastrozole, letrozole, aminoglutethimide, exemestane, formestane, testolactone. 2. Selective Estrogen Receptor Modulators (SERMs) including, but not limited to, raloxifene, tamoxifen, toremifene. 3. Other anti-estrogenic substances including, but not limited to, clomiphene, cyclofenil, fulvestrant. S5. DIURETICS AND OTHER MASKING AGENTS Masking agents are prohibited. They include: Diuretics*, epitestosterone, probenecid, alpha-reductase inhibitors (e.g. finasteride, dutasteride), plasma expanders (e.g. albumin, dextran, hydroxyethyl starch) and other substances with similar biological effect(s). Diuretics include: acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances with a similar chemical structure or similar biological effect(s) (except for drosperinone, which is not prohibited). * A Therapeutic Use Exemption is not valid if an Athlete’s urine contains a diuretic in association with threshold or sub-threshold levels of a Prohibited Substance(s). The Prohibited List 2007 September 16, 2006 7 PROHIBITED METHODS M1. ENHANCEMENT OF OXYGEN TRANSFER The following are prohibited: 1. Blood doping, including the use of autologous, homologous or heterologous blood or red blood cell products of any origin. 2. Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products). M2. CHEMICAL AND PHYSICAL MANIPULATION 1. Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Controls is prohibited. These include but are not limited to catheterisation, urine substitution and/or alteration. 2. Intravenous infusions are prohibited, except as a legitimate medical treatment. M3. GENE DOPING The non-therapeutic use of cells, genes, genetic elements, or of the modulation of gene expression, having the capacity to enhance athletic performance, is prohibited. The Prohibited List 2007 September 16, 2006 8 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the categories S1 to S5 and M1 to M3 defined above, the following categories are prohibited in competition: PROHIBITED SUBSTANCES S6. STIMULANTS All stimulants (including both their (D- & L-) optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2007 Monitoring Program*. Stimulants include: Adrafinil, adrenaline**, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, benzylpiperazine, bromantan, cathine***, clobenzorex, cocaine, cropropamide, crotetamide, cyclazodone, dimethylamphetamine, ephedrine****, etamivan, etilamphetamine, etilefrine, famprofazone, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine, fenproporex, furfenorex, heptaminol, isometheptene, levmethamfetamine, meclofenoxate, mefenorex, mephentermine, mesocarb, methamphetamine (D-), methylenedioxyamphetamine, methylenedioxymethamphetamine, p- methylamphetamine, methylephedrine****, methylphenidate, modafinil, nikethamide, norfenefrine, norfenfluramine, octopamine, ortetamine, oxilofrine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phenmetrazine, phenpromethamine, phentermine, 4- phenylpiracetam (carphedon), prolintane, propylhexedrine, selegiline, sibutramine, strychnine, tuaminoheptane and other substances with a similar chemical structure or similar biological effect(s). * The following substances included in the 2007 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol, pseudoephedrine, synephrine) are not considered as Prohibited Substances. ** Adrenaline associated with local anaesthetic agents or by local administration (e.g. nasal, ophthalmologic) is not prohibited. *** Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter. **** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter. The Prohibited List 2007 September 16, 2006 9 A stimulant not expressly mentioned as an example under this section should be considered as a Specified Substance only if the Athlete can establish that the substance is particularly susceptible to unintentional anti-doping rule violations because of its general availability in medicinal products or is less likely to be successfully abused as a doping agent. S7. NARCOTICS The following narcotics are prohibited: buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine. S8. CANNABINOIDS Cannabinoids (e.g. hashish, marijuana) are prohibited. S9. GLUCOCORTICOSTEROIDS All glucocorticosteroids are prohibited when administered orally, rectally, intravenously or intramuscularly. Their use requires a Therapeutic Use Exemption approval. Other routes of administration (intraarticular /periarticular/ peritendinous/ epidural/ intradermal injections and inhalation) require an Abbreviated Therapeutic Use Exemption except as noted below. Topical preparations when used for dermatological (including iontophoresis/phonophoresis), auricular, nasal, ophthalmic, buccal, gingival and perianal disorders are not prohibited and do not require any form of Therapeutic Use Exemption. The Prohibited List 2007 September 16, 2006 10 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. ALCOHOL Alcohol (ethanol) is prohibited in-competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) for each Federation is reported in parenthesis. • Aeronautic (FAI) (0.20 g/L) • Archery (FITA, IPC) (0.10 g/L) • Automobile (FIA) (0.10 g/L) • Boules (CMSB, (0.10 g/L) IPC bowls) • Karate (WKF) (0.10 g/L) • Modern Pentathlon (UIPM) (0.10 g/L) for disciplines involving shooting • Motorcycling (FIM) (0.10 g/L) • Powerboating (UIM) (0.30 g/L) P2. BETA-BLOCKERS Unless otherwise specified, beta-blockers are prohibited in-competition only, in the following sports. • Aeronautic (FAI) • Archery (FITA, IPC) (also prohibited out-of-competition) • Automobile (FIA) • Billiards (WCBS) • Bobsleigh (FIBT) • Boules (CMSB, IPC bowls) • Bridge (FMB) • Curling (WCF) • Gymnastics (FIG) • Motorcycling (FIM) • Modern Pentathlon (UIPM) for disciplines involving shooting • Nine-pin bowling (FIQ) • Sailing (ISAF) for match race helms only • Shooting (ISSF, IPC) (also prohibited out-of-competition) • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Wrestling (FILA) Beta-blockers include, but are not limited to, the following: acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol. The Prohibited List 2007 11 September 16, 2006 SPECIFIED SUBSTANCES* “Specified Substances”* are listed below: • All inhaled Beta-2 Agonists, except salbutamol (free plus glucuronide) greater than 1000 ng/mL and clenbuterol; • Probenecid; • Cathine, cropropamide, crotetamide, ephedrine, etamivan, famprofazone, heptaminol, isometheptene, levmethamfetamine, meclofenoxate, p-methylamphetamine, methylephedrine, nikethamide, norfenefrine, octopamine, ortetamine, oxilofrine, phenpromethamine, propylhexedrine, selegiline, sibutramine, tuaminoheptane, and any other stimulant not expressly listed under section S6 for which the Athlete establishes that it fulfils the conditions described in section S6; • Cannabinoids; • All Glucocorticosteroids; • Alcohol; • All Beta Blockers. * “The Prohibited List may identify specified substances which are particularly susceptible to unintentional anti-doping rule violations because of their general availability in medicinal products or which are less likely to be successfully abused as doping agents.” A doping violation involving such substances may result in a reduced sanction provided that the “…Athlete can establish that the Use of such a specified substance was not intended to enhance sport performance…” THE 2007 PROHIBITED LIST SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) UAnabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: PROHIBITED METHODS SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the categories S1 to S5 and M1 to M3 defined above, the following categories are prohibited in competition: US6. STIMULANTS US8. CANNABINOIDS US9. GLUCOCORTICOSTEROIDS All glucocorticosteroids are prohibited when administered orally, rectally, intravenously or intramuscularly. Their use requires a Therapeutic Use Exemption approval. Other routes of administration (intraarticular /periarticular/ peritendinous/ epidural/ intradermal injections and inhalation) require an Abbreviated Therapeutic Use Exemption except as noted below. Topical preparations when used for dermatological (including iontophoresis/phonophoresis), auricular, nasal, ophthalmic, buccal, gingival and perianal disorders are not prohibited and do not require any form of Therapeutic Use Exemption. UP1. ALCOHOL Aeronautic (FAI) (0.20 g/L) Archery (FITA, IPC) (0.10 g/L) Automobile (FIA) (0.10 g/L) Boules (CMSB, (0.10 g/L) IPC bowls) Karate (WKF) (0.10 g/L) Modern Pentathlon (UIPM) (0.10 g/L) for disciplines involving shooting Motorcycling (FIM) (0.10 g/L) Powerboating (UIM) (0.30 g/L) UP2. BETA-BLOCKERS All inhaled Beta-2 Agonists, except salbutamol (free plus glucuronide) greater than 1000 ng/mL and clenbuterol; Probenecid; p-methylamphetamine, methylephedrine, nikethamide, norfenefrine, octopamine, ortetamine, oxilofrine, phenpromethamine, propylhexedrine, selegiline, sibutramine, tuaminoheptane, and any other stimulant not expressly listed under section S6 for which th... Cannabinoids; Alcohol; All Beta Blockers.

  • wada_2007_list_modifications.pdf
    1 September 16th, 2006 2007 Prohibited List Summary of Major Modifications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) S1. Anabolic Steroids • The explanatory paragraphs 4 and 5 of this section have been reworded for clarity purposes. S5. Diuretics • For clarity purposes, the introductory sentence and first paragraph have been reworded. M2. Chemical and physical manipulation • The word “acute” has been removed from the paragraph on intravenous infusions, since the legitimate use of this method for medical purposes should be left to the judgement of the acting physician. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION S6. Stimulants • The wording of this section is changed to more clearly define the prohibited status of stimulants. In this regard, it is stated that: All stimulants (including both their (D- & L-) optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2007 Monitoring Program. This is followed by a non-limiting list of examples. The possibility that stimulants not included within the examples may in certain instances be considered a Specified Substance is contemplated by the last added paragraph in this section: A stimulant not expressly mentioned as an example under this section should be considered as a Specified Substance only if the athlete can establish that the substance is particularly susceptible to 2 unintentional anti-doping rule violations because of its general availability in medicinal products or is less likely to be successfully abused as a doping agent. • Benzylpiperazine, already considered a prohibited substance, has been added as example. • Tuaminoheptane, an alpha-agonist, used in some countries for the treatment of nasal congestion, is added as a new example of stimulant. This substance is also included in the list of Specified Substances. • 4-Phenylpiracetam, the chemical name of carphedon, has been added for clarification purposes. • A clarification on the permitted status of imidazole derivatives has been added. S9. Glucocorticosteroids • A series of additional examples of glucocorticosteroid routes of administration has been added to provide better guidance to TUE and ATUE applications. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. Alcohol • At the request of the WCBS, Billiards is removed from this section. • It is clarified that the doping violation thresholds listed correspond to haematological values. P2. Beta-Blockers • At the request of the FIDE, Chess is removed from this section. SPECIFIED SUBSTANCES • It is clarified that the beta-2-agonist salbutamol by inhalation is not a specified substance at urinary levels greater than 1000 ng/mL. • The stimulant tuaminoheptane (section S6) is added to the list of Specified Substances. • The paragraph listing the stimulants has been reworded for clarification in accordance with the wording changes made in the S6 section.

  • wada_2007_list_modifications.pdf
    1 September 16th, 2006 2007 Prohibited List Summary of Major Modifications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) S1. Anabolic Steroids • The explanatory paragraphs 4 and 5 of this section have been reworded for clarity purposes. S5. Diuretics • For clarity purposes, the introductory sentence and first paragraph have been reworded. M2. Chemical and physical manipulation • The word “acute” has been removed from the paragraph on intravenous infusions, since the legitimate use of this method for medical purposes should be left to the judgement of the acting physician. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION S6. Stimulants • The wording of this section is changed to more clearly define the prohibited status of stimulants. In this regard, it is stated that: All stimulants (including both their (D- & L-) optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2007 Monitoring Program. This is followed by a non-limiting list of examples. The possibility that stimulants not included within the examples may in certain instances be considered a Specified Substance is contemplated by the last added paragraph in this section: A stimulant not expressly mentioned as an example under this section should be considered as a Specified Substance only if the athlete can establish that the substance is particularly susceptible to 2 unintentional anti-doping rule violations because of its general availability in medicinal products or is less likely to be successfully abused as a doping agent. • Benzylpiperazine, already considered a prohibited substance, has been added as example. • Tuaminoheptane, an alpha-agonist, used in some countries for the treatment of nasal congestion, is added as a new example of stimulant. This substance is also included in the list of Specified Substances. • 4-Phenylpiracetam, the chemical name of carphedon, has been added for clarification purposes. • A clarification on the permitted status of imidazole derivatives has been added. S9. Glucocorticosteroids • A series of additional examples of glucocorticosteroid routes of administration has been added to provide better guidance to TUE and ATUE applications. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. Alcohol • At the request of the WCBS, Billiards is removed from this section. • It is clarified that the doping violation thresholds listed correspond to haematological values. P2. Beta-Blockers • At the request of the FIDE, Chess is removed from this section. SPECIFIED SUBSTANCES • It is clarified that the beta-2-agonist salbutamol by inhalation is not a specified substance at urinary levels greater than 1000 ng/mL. • The stimulant tuaminoheptane (section S6) is added to the list of Specified Substances. • The paragraph listing the stimulants has been reworded for clarification in accordance with the wording changes made in the S6 section.
  • keyboard_double_arrow_left
  • keyboard_arrow_left
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • keyboard_arrow_right
  • keyboard_double_arrow_right
  • email
Zuletzt aktualisiert: 23.07.2026
  • Kontakt & Anfahrt
Soziale Medien
  • Impressum
  • Datenschutz
  • Barrierefreiheit
  • north_east Hinweis geben
Partneruniversität für Spitzensport Akkreditierungsrat Weltoffene Hochschulen gegen Fremdenfeindlichkeit Familie in der Hochschule Global Sport University Network Kölner Wissenschaftsrunde HR Excellence in Research